Glucagon-like peptide 1 receptor agonist:A potential game changer for cholangiocarcinoma  

作　　者：Ronnakrit Trakoonsenathong Ching-Feng Chiu Charupong Saengboonmee 

机构地区：[1]Cho-Kalaphruek Excellent Research Project for Medical Students,Faculty of Medicine,Khon Kaen University,Khon Kaen 40002,Thailand [2]Department of Biochemistry,Faculty of Medicine,Khon Kaen University,Khon Kaen 40002,Thailand [3]Center for Translational Medicine,Faculty of Medicine,Khon Kaen University,Khon Kaen 40002,Thailand [4]Graduate Institute of Metabolism and Obesity Sciences,Taipei Medical University,Taipei 11031,Taiwan

出　　处：《World Journal of Gastroenterology》2024年第34期3862-3867,共6页世界胃肠病学杂志（英文版）

基　　金：Supported by Mekong-Lancang Cooperation Special Fund;Cho-Kalaphruek Excellent Research Project for Medical Students;The International Internship Pilot Program,No.IIPP2023283.

摘　　要：Glucagon-like peptide-1 receptor(GLP-1R)agonist,a subgroup of incretin-based anti-diabetic therapies,is an emerging medication with benefits in reducing blood glucose and weight and increasing cardiovascular protection.Contrarily,concerns have been raised about GLP-1R agonists increasing the risk of particular cancers.Recently,several epidemiological studies reported contradictory findings of incretin-based therapy on the risk modification for cholangiocarcinoma(CCA).The first cohort study demonstrated that incretin-based therapy was associated with an increased risk of CCA.Later studies,however,showed a null effect of incretinbased therapy on CCA risk for dipeptidyl peptidase-4 inhibitor nor GLP-1R agonist.Mechanistically,glucagon-like peptide 1 receptor is multifunctional,including promoting cell growth.High GLP-1R expressions were associated with progressive phenotypes of CCA cells in vitro.Unexpectedly,the GLP-1R agonist showed anti-tumor effects on CCA cells in vitro and in vivo with unclear mechanisms.Our recent report also showed that GLP-1R agonists suppressed the expression of GLP-1R in CCA cells in vitro and in vivo,leading to the inhibition of CCA tumor growth.This editorial reviews recent evidence,discusses the potential effects of GLP-1R agonists in CCA patients,and proposes underlying mechanisms that would benefit from further basic and clinical investigation.

关 键 词：CARCINOGENESIS CHOLANGIOCARCINOMA Diabetes mellitus INCRETIN Glucagon-like peptide 1 receptor 

分 类 号：R657.3[医药卫生—外科学]